Cures
Delivered.

Our team has expertise in CAR-T, TIL, NK, MSC, HSC, and iPSC-based cell therapies, as well as AAV, LVV, and other vectors used either in cell therapies or as drug products. Our experienced team will tailor your process for scale, consistency, optimization, and GMP readiness. Our experts minimize risks and delays while quickly demonstrating safety and efficacy.

Technology transfer involves transferring knowledge of processes or methods from development to manufacturing or between different sites, ensuring consistent product realization. We assist early-phase clients in avoiding typical tech transfer stumbling blocks and specialize in late-phase and commercial tech transfer for a smooth, large-scale transition. We challenge manufacturing limitations with scalable solutions that reduce costs and improve efficiency.

Our extensive viral vector services encompass lentiviral, AAV, and adenovirus platforms. We have experts who can help with the early-stage screening and optimization of production systems to identify the best elements for process development and manufacturing scale-up. Our MS&T and manufacturing teams will also work with you to tech transfer your existing processes and manufacture your vectors for clinical and commercial applications and our analytical development and testing teams will provide the analytical methodologies you need for titration and quality control.

By leveraging the in-house capabilities of Minaris Advanced Testing for biosafety and product characterization, we significantly reduce vein-to-vein time and expedite autologous product release while minimizing costs and mitigating the risks associated with third-party testing. Technical and regulatory insights and custom or standard services are implemented across every development and manufacturing program to ensure that analytical and QC considerations are managed efficiently and expertly.

Access our unique IP, for which we currently hold over 22 patents related to DNA engineering, plasmids, cell lines, and our proprietary technologies: XOFLX™ and TESSA®. XOFLX™ stable technology and the corresponding packaging and producer cell lines offer a simplified, high-yield LVV manufacturing system. TESSA^® (Tetracycline-Enabled Self-Silencing Adenovirus) technology delivers high-titer and high-quality AAV to gene therapy pioneers.

The team at Minaris Advanced Therapies has designed and synthesized more than 28,000+ plasmid constructs. You can purchase Minaris’ SnapFast™ off-the-shelf (OTS) plasmids or work with our team to develop custom plasmids. The SnapFast™ modular plasmids are designed to work like ‘molecular building blocks’, using a catalogue of well characterized DNA elements that can be easily and reliably inserted into specific locations within the plasmid to generate large numbers of custom constructs across a range of expression platforms.

Minaris Advanced Testing provides comprehensive analytical method development, biosafety testing, and product characterization for viral vectors, cell therapies, mAbs, proteins, and viral vaccines. We remain ahead of evolving regulatory requirements and best practices. Our services include raw material testing, cell line characterization, viral clearance, potency assays, stability assessments, cell banking, and lot release testing. They are provided to companies that manufacture with us and those that manufacture in-house or at a fellow CDMO.